Kala Study for Persistent Corneal Epithelial Defect

Trial ID:
Peter Krall, MD
The purpose of this study is to evaluate the safety and effectiveness of two doses (low and high) of the investigational KPI-012 eye drop for the treatment of persistent corneal epithelial defects (PCED). PCED is a wound on the front surface of the eye (cornea) that is not healing.

Inclusion Criteria

Patients must:

  • Be 18 or older.
    Have medically documented PCED.
    Be willing to stop current medications.

Exclusion Criteria

Patients must not:

  • Use any other eye medications other than the study eye drops.
    Have used Oxervate within 30 days.
    Have had any surgical procedures for PCED.

Additional Info

Participants will be randomized (like the flip of a coin) to the study eye drops or placebo eye drops (no active ingredient).

An antibiotic eyedrop and artificial tear eyedrop will be provided by the study in addition to the study eyedrop.

Search NCT 05727878 at https://clinicaltrials.gov website for more information.

Contact Info:

  • Clinical Research Services
  • CRSLeadership@scrippshealth.org